|
Squamous cell carcinoma of esophagus
|
0.400 |
Biomarker
|
disease |
BEFREE |
Influence of apoptosis (BCL2, FAS), cell cycle (CCND1) and growth factor (EGF, EGFR) genetic polymorphisms on survival outcome: an exploratory study in squamous cell esophageal cancer.
|
17912028 |
2007 |
|
Squamous cell carcinoma of esophagus
|
0.400 |
Biomarker
|
disease |
BEFREE |
Moreover, we observed that triptolide induced ESCC cell cycle arrest at the G1/S phase and apoptosis through cyclin D1-CDK4/6 regulation and caspases activation.
|
30779917 |
2019 |
|
Squamous cell carcinoma of esophagus
|
0.400 |
Biomarker
|
disease |
BEFREE |
E2F transcription factor 8 promotes cell proliferation via CCND1/p21 in esophageal squamous cell carcinoma.
|
30532557 |
2018 |
|
Squamous cell carcinoma of esophagus
|
0.400 |
Biomarker
|
disease |
BEFREE |
In this study, we clarified the clinical significance of FBXO31 and characterized the association between cyclin D1 and FBXO31 in ESCC cases.
|
21537837 |
2011 |
|
Squamous cell carcinoma of esophagus
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
CDK4/6 inhibitor-SHR6390 exerted potential antitumor activity against ESCC cell lines and xenografts, and evaluation of CDK6 and Cyclin D1 expressions might be helpful to select patients beneficial from SHR6390, which provided evidences for future clinical trials.
|
28578693 |
2017 |
|
Squamous cell carcinoma of esophagus
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The overexpression of miR-375 downregulated MTDH (P<0.01), cyclin D1 (P<0.05) and vascular endothelial growth factor (P<0.01) expression, while upregulating epithelial cadherin (P<0.01) expression, which may account for its effect on ESCC cell proliferation and invasion.
|
28599478 |
2017 |
|
Squamous cell carcinoma of esophagus
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our findings reveal a molecular basis for cancer therapy through targeting glutaminolysis and mitochondrial respiration in ESCC with dysregulated Fbxo4-cyclin D1 axis as well as cancers resistant to CDK4/6 inhibitors.
|
30899002 |
2019 |
|
Squamous cell carcinoma of esophagus
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
This study aims to analyze the combined prognostic significance of cyclinD1 (CCND1) DNA amplification and the co-alteration of CCND1/pRb/ppRB in patients with esophageal squamous cell carcinoma.
|
22150974 |
2013 |
|
Squamous cell carcinoma of esophagus
|
0.400 |
Biomarker
|
disease |
BEFREE |
Seventeen (34%) of the 50 ESCC primary lesions were cyclin D1-positive, while 33 (66%) were cyclin D1-negative.
|
11295092 |
2001 |
|
Squamous cell carcinoma of esophagus
|
0.400 |
Biomarker
|
disease |
BEFREE |
Here we identify that Wnt2/beta-catenin signaling pathway is activated in ESCC cells, and sodium nitroprusside (SNP) and siRNA against beta-catenin not only inhibit the expressions of beta-catenin and its major downstream effectors including c-myc and cyclin D1, but induce cell cycle arrest and apoptosis, suggesting that Wnt2/beta-catenin pathway may be a potential molecular target for ESCC therapy.
|
19857041 |
2010 |
|
Squamous cell carcinoma of esophagus
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Determination of the cyclin D1 (G870A) single nucleotide polymorphism may be suitable to identify individuals with increased risk for ESCC or CAC in the northern Chinese population.
|
12673692 |
2003 |
|
Squamous cell carcinoma of esophagus
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The expression pattern of AQP5 and p21 protein was sharply contrasted, but AQP5 and CCND1 protein expression showed a similar pattern in ESCC tissue.
|
23657608 |
2014 |
|
Squamous cell carcinoma of esophagus
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We investigated whether the putative transforming gene MYEOV, mapping 360 kb centromeric to CCND1 and activated concomitantly with CCND1 in a subset of t(11;14)(q13;q32) positive multiple myeloma cell lines, represents a target of 11q13 amplification in ESC.
|
12202983 |
2002 |
|
Squamous cell carcinoma of esophagus
|
0.400 |
Biomarker
|
disease |
BEFREE |
We immunohistochemically examined p57KIP2 (p57) expression in 92 patients with human esophageal squamous cell carcinoma (SCC) to determine the relationship between this expression and those of cyclin D1 and E. The p57 labeling index (LI) (defined as the percentage of p57-positive cells) in esophageal SCC was 43.3 +/- 3.2% (mean +/- standard error of the mean).
|
10928132 |
2000 |
|
Squamous cell carcinoma of esophagus
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Epidermal growth factor receptor and cyclin D1 are independently amplified and overexpressed in esophageal squamous cell carcinoma.
|
15672286 |
2005 |
|
Squamous cell carcinoma of esophagus
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Further investigation in the effect of miR-503 on ESCC cell proliferation, migration, and invasion showed that enhanced expression of miR-503 inhibited ESCC aggressive phenotype and overexpression of CCND1 reversed the effect of miR-503-mediated ESCC cell aggressive phenotype.
|
28602785 |
2017 |
|
Squamous cell carcinoma of esophagus
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
CCND1 and PTEN genetic polymorphisms might induce susceptibility to the occurrence of esophageal squamous cell carcinoma (ESCC).
|
24391010 |
2013 |
|
Squamous cell carcinoma of esophagus
|
0.400 |
Biomarker
|
disease |
BEFREE |
To analyze the relationship between cysteine-rich 61 (Cyr61) and target genes of Wnt/β-catenin pathway (CCND1 and MYC) in 40 esophageal squamous cell carcinoma (ESCC) tissue specimens.
|
27721245 |
2016 |
|
Squamous cell carcinoma of esophagus
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Cyclin D1 level correlated with Pin1 expression in clinical ESCC specimens.
|
25160749 |
2014 |
|
Squamous cell carcinoma of esophagus
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In this study, we investigated the expression pattern of beta-catenin and cyclin D1 using immunohistochemistry and searched for mutations in exon 3 of the beta-catenin gene and Axin gene in esophageal squamous cell carcinoma.
|
17309796 |
2007 |
|
Squamous cell carcinoma of esophagus
|
0.400 |
Biomarker
|
disease |
BEFREE |
Therefore, <i>SOX2</i> might be considered as a potential prognostic indicator and a potential target for therapeutic targets in ESCC. p53 staining and combined p53 and Cyclin D1 expression had significantly unfavorable prognostic value for patients with ESCC.
|
30210237 |
2018 |
|
Squamous cell carcinoma of esophagus
|
0.400 |
Biomarker
|
disease |
BEFREE |
Amplification of cyclin D1 was detected in 28 (23%) of 122 cases of squamous cell carcinoma of the esophagus.
|
9816282 |
1996 |
|
Squamous cell carcinoma of esophagus
|
0.400 |
Biomarker
|
disease |
BEFREE |
Immunoreactivities of cyclin D1 and pRB were evaluated in 148 surgically resected ESCC by use of monoclonal antibodies.
|
11570573 |
2001 |
|
Squamous cell carcinoma of esophagus
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Previous studies have found a 3-10-fold amplification and overexpression of the cyclin D1 gene in about 32% of human esophageal squamous cell carcinoma.
|
8781742 |
1996 |
|
Squamous cell carcinoma of esophagus
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Xanthohumol also decreased expression of cyclin D1 and increased the levels of cleaved caspase-3, -7 and -PARP as well as Bax, Bim<sub>s</sub> and cytochrome c in ESCC cells by downregulating AKT signaling targets, including glycogen synthase kinase 3 beta (GSK3β), mammalian target of rapamycin, and ribosomal protein S6 (S6K).
|
30887517 |
2019 |